Alnyalm, Vir partner on RNAi-based drugs for infectious diseases
October 18, 2017 at 08:44 AM EDT
Oct 18 (Reuters) - Drug developer Alnylam Pharmaceuticals Inc entered into an agreement with privately held Vir Biotechnology on Wednesday to develop a new class of RNAi-based treatments for infectious diseases, including chronic hepatitis B.
